Navigation Links
AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA
Date:11/29/2007

WILMINGTON, Del., Nov. 29 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the United States (US) Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market ARIMIDEX(R) (anastrozole) for its licensed breast cancer indications until June 2010. Prior to pediatric exclusivity being granted by the FDA, the patent was due to expire in December 2009.

ARIMIDEX is currently approved in the US for the for the following indications:

-- The adjuvant treatment (treatment following surgery with or without

radiation) of postmenopausal women with hormone receptor positive early

breast cancer (Sub Part H approval granted in 2002, final approval in

2005).

-- The first-line treatment of postmenopausal women with hormone receptor

positive or hormone receptor unknown locally advanced or metastatic

breast cancer (granted in 2000).

-- The treatment of advanced breast cancer in postmenopausal women with

disease progression following tamoxifen therapy. Patients with hormone

receptor-negative disease and patients who did not previously respond

to tamoxifen therapy rarely responded to ARIMIDEX (granted in 1995).

Dr. John Patterson, Executive Director of Development at AstraZeneca said "Pre-clinical and clinical data supported the investigation of the therapeutic potential of ARIMIDEX in pediatric conditions that manifest symptoms resulting from increased estrogen production, for example: gynecomastia in pubertal boys and precocious puberty in girls with McCune-Albright Syndrome (MAS). While pleased to have been able to work with the FDA in investigating the potential benefits of ARIMIDEX in these settings, AstraZeneca will not be seeking an indication in either of these pediatric conditions based on trial results."

In the US, ARIMIDEX sales reached $507 million for the nine months of 2007. ARIMIDEX has a
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. AstraZeneca Leads Local Walking Movement
2. AstraZeneca Joins Local Walking Movement
3. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
4. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
5. AstraZeneca Recognized as One of Working Mothers 100 Best Companies for the Sixth Consecutive Year
6. AstraZeneca Launches New Program to Support Facilities that Connect People to Needed Medical Care and Prescription Assistance
7. NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
8. Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca
9. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
10. AstraZeneca Response to November 2, 2007 Ruling In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, U.S. District Court, District of Massachusetts
11. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Slone Partners , ... medicine, healthcare information technology, and laboratory testing industries, ... Chief Operating Officer. The announcement comes after a ... a strengthened presence in Boston and several new ... and breathes the client experience," said Adam Slone, ...
(Date:12/19/2014)... 19, 2014 This is a professional ... global Gliquidone industry with a focus on the Chinese ... status of the Gliquidone manufacturers and is a valuable ... interested in the industry. , Firstly, the report provides ... applications and manufacturing technology. Then, the report explores the ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 The ... ski club in Southern Vermont’s Deerfield Valley, announced today ... inspired by classic rock songs. , Three time ... with a private concert followed by a trail naming ... new trail names include: “I’m Alright” the theme song ...
(Date:12/19/2014)... new study suggests a possible link between certain menopause ... sweats -- and higher rates of hip fractures and ... affecting about 60 percent of women. The hormonal changes ... then face a higher risk of weakened bones and ... or severe menopausal symptoms are more likely to have ...
(Date:12/19/2014)... Amy Norton HealthDay ... Children born to moms who were exposed to high levels ... risk of developing autism, a U.S. study suggests. Researchers ... between 1990 and 2002, those exposed to the most air ... baby who later developed autism. And exposure during the third ...
Breaking Medicine News(10 mins):Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3
... ALLEGAN, Mich., Jan. 28 Perrigo Company (Nasdaq: ... its Board of Directors declared a quarterly dividend ... 2009 to shareholders of record on February 27, ... healthcare supplier that develops, manufactures and distributes over-the-counter ...
... has been linked to cancer, diabetes, heart disease, developmental ... A, a controversial chemical used to harden plastics for ... appears to remain in the body much longer than ... that exposure to BPA may come from many different ...
... 28 PEAK Surgical, Inc., a medical,device company ... based on a,proprietary technology, announced today that it ... Surgery System for use in general surgery. The ... PEAK PlasmaBlade(TM),family of disposable, low-temperature surgical cutting and ...
... Venture Industry to Step Up Investments in Healthcare Services ... is on the verge of building a "new healthcare ... venture capital firm Psilos Group. But the same report ... Obama administration, the economics of healthcare will not truly ...
... Corporation, a leader in innovative fatigue management solutions for ... has chosen REM Medical as its provider of comprehensive ... obstructive sleep apnea (OSA) diagnostic and treatment services for ... of this serious sleep disorder. The Federal Motor ...
... Snoring Events, Increase in Sleep Quality For Bed ... of Brez premium nasal breathing aids, the first ... proven to reduce snoring and increase overall sleep ... in all Rite Aid and numerous independent pharmacies ...
Cached Medicine News:Health News:Controversial Chemical Lingers Longer in the Body: Study 2Health News:Controversial Chemical Lingers Longer in the Body: Study 3Health News:PEAK Surgical Receives European CE Mark for PEAK(R) Surgery System for Use in General Surgery 2Health News:PEAK Surgical Receives European CE Mark for PEAK(R) Surgery System for Use in General Surgery 3Health News:Obama Reforms Could Spark 'New Healthcare Economy' If Investors Increase Funding, Says Leading Healthcare Venture Firm 2Health News:Obama Reforms Could Spark 'New Healthcare Economy' If Investors Increase Funding, Says Leading Healthcare Venture Firm 3Health News:Obama Reforms Could Spark 'New Healthcare Economy' If Investors Increase Funding, Says Leading Healthcare Venture Firm 4Health News:Gordon Trucking Begins Sleep Apnea Wellness Program with REM Medical Corporation 2Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 2Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 3Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 4
(Date:12/19/2014)... 18, 2014 Somewhere between dropping five pounds ... forgotten. But Audicus , a next-generation hearing aids ... new year. Hearing loss is the third ... though it is often unaddressed. Forty-eight million Americans have ... hearing aid, mainly due to price. Hearing aids traditionally ...
(Date:12/19/2014)... , Dec. 18, 2014  Sage Analytics ... generation of equipment for the testing of marijuana ... of the new Luminary™ Profiler, the industry,s first ... measurement in a cost-effective, portable unit. ... specific needs of the cannabis industry, the Luminary™ ...
(Date:12/19/2014)... Capnia, Inc. (NASDAQ: CAPN ... based on its proprietary Sensalyze™ Technology Platform for ... results for the third quarter and nine months ... completion of our initial public offering (IPO), we ... initiated CoSense® commercial launch," said Anish Bhatnagar, M.D., ...
Breaking Medicine Technology:Audicus Will Help People Resolve to Hear Better in 2015 2Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... - Appoints Director, Clinical Operations and Manager, Medical ... Cellectar LLC, (Cellectar), a,privately-held radiopharmaceuticals company that designs ... cancers, today announced the,appointment of Ernest Allen as ... Medical Affairs. These appointments reflect the,advancement of the ...
... Calif., Oct. 3 Anthera Pharmaceuticals,Inc., a privately-held ... inflammatory diseases,announced today the completion of enrollment and ... its lead compound, A-002 for stable coronary,artery disease. ... the end of,the year. "We are pleased ...
Cached Medicine Technology:Cellectar Expands Clinical Management Team 2Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 2Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 3
... a multifunctional hybrid configuration, consisting of ... a SOMATOM CT Scanner with Sliding ... to radiation treatment delivery, providing accurate, ... treatment room. The Siemens PRIMATOM System ...
... SOMATOM Sensation is the highly respected ... coronary branches to visualizing plaque. With its ... industrys fastest rotation time of 0.33s, virtually ... z-Sharp Technology, the system delivers unprecedented diagnostic ...
... (DGH 55) is the ultimate in portable pachymeters. ... in weight. The Pachmate is a handheld pachymeter ... The Pachmate will easily fit in a lab ... rugged in design and one of the worlds ...
... integrated system that will perform venous occlusion ... You no longer need to manually control ... with and without reactive hyperemia are included. ... for measurements and the frequency with which ...
Medicine Products: